MA39085B1 - Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne - Google Patents

Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne

Info

Publication number
MA39085B1
MA39085B1 MA39085A MA39085A MA39085B1 MA 39085 B1 MA39085 B1 MA 39085B1 MA 39085 A MA39085 A MA 39085A MA 39085 A MA39085 A MA 39085A MA 39085 B1 MA39085 B1 MA 39085B1
Authority
MA
Morocco
Prior art keywords
combination
cineol
amoxicillin
treatment
bacterial infection
Prior art date
Application number
MA39085A
Other languages
English (en)
Other versions
MA39085A1 (fr
Inventor
Remmal Adnane
Amin Akhmouch Ahmed
Original Assignee
Advanced Scient Developements
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developements filed Critical Advanced Scient Developements
Priority to MA39085A priority Critical patent/MA39085B1/fr
Priority to US16/306,262 priority patent/US11872216B2/en
Priority to CA3026323A priority patent/CA3026323A1/fr
Priority to CN201780041549.7A priority patent/CN109562182A/zh
Priority to BR112018074913-3A priority patent/BR112018074913A2/pt
Priority to MA044286A priority patent/MA44286A/fr
Priority to EA201892808A priority patent/EA201892808A1/ru
Priority to JP2019515760A priority patent/JP7033586B2/ja
Priority to PCT/MA2017/000014 priority patent/WO2017209588A2/fr
Priority to EP17743405.7A priority patent/EP3463479A2/fr
Publication of MA39085A1 publication Critical patent/MA39085A1/fr
Publication of MA39085B1 publication Critical patent/MA39085B1/fr
Priority to US18/408,636 priority patent/US20240148702A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison de cinéol et d' amoxicilline pour une utilisation dans le traitement d'une infection bactérienne chez un sujet. La présente combinaison peut en outre comprendre un inhibiteur de p-lactamases, de préférence de l'acide clavulanique. La combinaison selon l'invention permet en particulier de lutter contre les infections causées par des bactéries résistantes aux antibiotiques, de préférence aux antibiotiques de la famille des p-lactamines.
MA39085A 2016-06-02 2016-06-02 Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne MA39085B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MA39085A MA39085B1 (fr) 2016-06-02 2016-06-02 Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne
MA044286A MA44286A (fr) 2016-06-02 2017-06-02 Formulation pharmaceutique de cinéol et d'amoxicilline
CA3026323A CA3026323A1 (fr) 2016-06-02 2017-06-02 Formulation pharmaceutique de cineol et d'amoxicilline
CN201780041549.7A CN109562182A (zh) 2016-06-02 2017-06-02 包含桉树脑和阿莫西林的药物制剂
BR112018074913-3A BR112018074913A2 (pt) 2016-06-02 2017-06-02 formulação farmacêutica de cineol e amoxicilina
US16/306,262 US11872216B2 (en) 2016-06-02 2017-06-02 Pharmaceutical formulation comprising cineole and amoxicillin
EA201892808A EA201892808A1 (ru) 2016-06-02 2017-06-02 Фармацевтический препарат, включающий цинеол и амоксициллин
JP2019515760A JP7033586B2 (ja) 2016-06-02 2017-06-02 シネオールとアモキシシリンとを含む医薬製剤
PCT/MA2017/000014 WO2017209588A2 (fr) 2016-06-02 2017-06-02 Formulation pharmaceutique de cinéol et d'amoxicilline
EP17743405.7A EP3463479A2 (fr) 2016-06-02 2017-06-02 Formulation pharmaceutique de cinéol et d'amoxicilline
US18/408,636 US20240148702A1 (en) 2016-06-02 2024-01-10 Pharmaceutical formulation comprising cineole and amoxicillin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA39085A MA39085B1 (fr) 2016-06-02 2016-06-02 Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne

Publications (2)

Publication Number Publication Date
MA39085A1 MA39085A1 (fr) 2017-12-29
MA39085B1 true MA39085B1 (fr) 2018-06-29

Family

ID=61167677

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39085A MA39085B1 (fr) 2016-06-02 2016-06-02 Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne

Country Status (2)

Country Link
EA (1) EA201892808A1 (fr)
MA (1) MA39085B1 (fr)

Also Published As

Publication number Publication date
EA201892808A1 (ru) 2019-05-31
MA39085A1 (fr) 2017-12-29

Similar Documents

Publication Publication Date Title
EA201991523A1 (ru) Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MX362683B (es) Composiciones farmacéuticas que comprenden antibiótico de beta-lactama, sulbactama e inhibidor de beta-lactamasa.
BR112017010132A2 (pt) terapia combinada para tratamento de infecções bacterianas resistentes
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
EP3409666A3 (fr) Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation
FR3029790B1 (fr) Microbille d'hydrogel de chitosane
PH12019500558A1 (en) Beta-lactamase inhibitor compounds
RU2015102562A (ru) Фармацевтические композиции и способ лечения маститов
CA3010327A1 (fr) Pyrimidines a substitution aryle a utiliser dans une infection par le virus de la grippe
WO2021022163A3 (fr) Composés et leurs utilisations
WO2015024010A3 (fr) Composés d'acide hydroxamique substitués
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
WO2017218922A8 (fr) Composés et méthodes pour le traitement d'infections bactériennes
MA49373A (fr) Compositions comprenant des souches bactériennes
EP4272831A3 (fr) Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2022006109A (es) Derivados 1-aminosulfonil-2-carboxipirrol como inhibidores de metalo-beta-lactamasa.
WO2014165126A3 (fr) 3-styryl-céphalosporines dérivées
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
WO2018109042A3 (fr) Peptides antimicrobiens
MX2019007361A (es) Composiciones para el cuidado bucal.
PH12019500331A1 (en) Beta-lactamase inhibitors
WO2015130547A8 (fr) Compositions de composés de guanidine bis-cyclique, méthodes d'utilisation et de traitement associées
MA39085A1 (fr) Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne